This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Interaction in Relation to Bone Marrow Depression

Boston Collaborative Drug Surveillance Program

JAMA. 1974;227(9):1036-1040.

Abstract
In 160 patients with neoplastic diseases (other than leukemia) that were treated with cytotoxic drugs, bone marrow depression (BMD) was more common in 65 patients who also received allopurinol than in 95 who did not (P<.005). In 58 patients who received cyclophosphamide, the frequencies of BMD in allopurinol recipients and nonrecipients were 57.7% and 18.8%, respectively. A similar but less pronounced trend occurring with other cytotoxic drugs involved too few patients with any one drug to allow firm conclusions. Interaction between allopurinol and cytotoxic drugs is a possible explanation of these findings.

Author Affiliations
From the Boston Collaborative Drug Surveillance Program, Boston University Medical Center.

Footnotes
For a complete list of participants in the program, see page 1040.

Reprint requests to Boston Collaborative Drug Surveillance Program, 400 Totten Pond Rd, Waltham, MA 02154.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of Bone Marrow Toxic Reaction in Patients Treated With Allopurinol
Stolbach et al.
JAMA 1982;247:334-336.
ABSTRACT  

Toxic Epidermal Necrolysis Associated With Allopurinol Administration
Ellman et al.
Arch Dermatol 1975;111:986-990.
ABSTRACT